TX-MARY-KAY-INC
11.8.2021 15:06:07 CEST | Business Wire | Press release
In 2021, Mary Kay Inc. continued its decades-long commitment to enriching the lives of women around the globe, manufacturing irresistible products and building healthier, more sustainable communities even in response to COVID-19. In recognition of Mary Kay’s achievements in the last six months, the brand has taken home several coveted awards in the business, corporate citizenship, and leadership categories from various prestigious organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005163/en/
The awards, which range from recognition of the brand’s COVID-19 response to accolades for a Mary Kay-produced documentary on the Gulf of Mexico’s preservation efforts, highlight the company’s unwavering business values and its dedication to the principles defined by the brand’s legendary founder, Mary Kay Ash.
Latest awards include:
COVID-19 Response Awards
-
Silver Globee® Winner – 13th
Annual 2021
Golden Bridge Business and Innovation Awards
- Team of the Year During COVID-19 (Hand Sanitizer Distribution Team)
- Company Response of the Year (Mary Kay Inc.)
- Best Product To Combat and Reduce the Impact of COVID-19 (Mary Kay Hand Sanitizer)
-
Gold Globee® Winner – 13th
Annual 2021
Golden Bridge Business and Innovation Awards
- Best Non-Profit Response Helping Local Communities and the World During COVID-19 (The Mary Kay FoundationSM )
-
Silver Globee® Winner – 6th
Annual 2021 American Best in Business Awards
- Team of the Year During COVID-19 (Hand Sanitizer Distribution Team)
- Company Response of the Year (Mary Kay Inc.)
- Best Product to Combat and Reduce the Impact of COVID-19 (Mary Kay Hand Sanitizer)
-
Gold Globee® Winner – 6th
Annual 2021 American Best in Business Awards
- Best Non-Profit Response Helping Local Communities and the World During COVID-19 (The Mary Kay FoundationSM )
Company Awards
- America's Best Mid-Sized Employers 2021 – Forbes
- “Power of Woman” Award, Mary Kay Ukraine, joint project with Marie Claire - X-RAY Marketing Awards
- The Best Employer 2021, Mary Kay Poland – The Financial Magazine
- “ Direct Sales Cosmetic Company Number One Award,” Mary Kay Belarus – “Number One” Annual National Awards
Sustainability Awards
Guardians of the Gulf, an eye-opening documentary that explores the tumultuous relationship between the Gulf of Mexico and the conservationists determined to protect it, has received various awards. Mary Kay Inc., serving as executive producer, with Media One in partnership with The Nature Conservancy, visited the coasts of Texas, Alabama and Mexico to shed light on the often-untold stories of Gulf preservation.
- Silver: Non-Broadcast General-Nature/Wildlife – Telly Awards
- Bronze: Non-Broadcast General-Documentary – Telly Awards
- Best Special Focus Documentary Finalist – LA Femme International Film Festival
- World Remi Award – Worldfest Houston International Film Festival
Leadership Recognition
- “67 Powerful Black Women CEOs And Executives In Corporate America,” Julia Simon, Chief Legal Officer and Corporate Secretary / Sheryl Adkins-Green, Chief Marketing Officer – Business Insider
- “TOP Women CEOs in Ukraine” in Women’s Leadership in the Corporate Sector and Business rating - Viktoriia Zoria-Iatsenko, General Manager, Mary Kay Ukraine – WoMo (The Portal for Working Women)
- “50 Most Valuable Women in Poland,” Ewa Kudlińska-Pyrz, General Manager, Mary Kay Poland – The Financial Magazine
- “The Top 100 Women Leaders In Consumer Products Of 2021,” Allyson Sellers, Vice President of Sales, Mary Kay U.S. – Women We Admire
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005163/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom